Ubamatamab (MUC16xCD3 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase I dose-escalation study

被引：2

作者：

O'Cearbhaill, R. E. ^{[1
,2
]}

Moore, K. N. ^{[3
,4
]}

Yeku, O. ^{[5
]}

Liu, J. F. ^{[6
]}

Bouberhan, S. ^{[5
]}

Hamilton, E. P. ^{[7
]}

Hou, J. Y. ^{[8
]}

Van Nieuwenhuysen, E. ^{[9
]}

Papadimitriou, K. ^{[10
]}

Yoo, S-Y. ^{[11
]}

Govindraj, S. ^{[11
]}

Brouwer-Visser, J. ^{[11
]}

Peterman, M. ^{[11
]}

Schmidt, T. ^{[11
]}

Barnes, B. ^{[11
]}

Madia, P. ^{[11
]}

Zhu, M. ^{[11
]}

Uldrick, T. S. ^{[11
]}

Miller, E. A. ^{[11
]}

O'Malley, D. ^{[12
,13
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA

[2] Weill Cornell Med Coll, New York, NY USA

[3] Univ Oklahoma, Hlth Sci Ctr, Stephenson Canc Ctr, Oklahoma City, OK USA

[4] Sarah Cannon Res Inst, Oklahoma City, OK USA

[5] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[6] Dana Farber Canc Inst, Med Oncol, Boston, MA USA

[7] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN 5 USA

[8] Columbia Univ, Div Gynecol Oncol, Med Ctr, New York, NY USA

[9] Leuven Canc Inst, Dept Oncol, Leuven, Belgium

[10] Univ Antwerp Hosp, Multidisciplinary Oncol Ctr Antwerp MOCA, Antwerp, Belgium

[11] Regeneron Pharmaceut Inc, Global Dev, Tarrytown, NY USA

[12] Ohio State Univ, Div Gynecol Oncol, Columbus, OH USA

[13] James Canc Ctr, Columbus, OH USA

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.1933

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

754P

引用

页码：S516 / S517

页数：2

共 50 条

[1] Ubamatamab (MUC16XCD3 bispecific antibody) with or without cemiplimab (Anti-PD-1 antibody) in recurrent ovarian cancer: phase 1 clinical and biomarker results
Liu, Joyce
O'Malley, David
Van Nieuwenhuysen, Els
Moore, Kathleen
Hamilton, Erika
Yeku, Oladapo
Bouberhan, Sara
Hou, June
Schroeder, David
Wang, Bin
Yoo, Suk-Young
Govindraj, Shilpa
Brouwer-Visser, Jurriaan
Peterman, Mary
Schmidt, Tamara
Barnes, Brigid
Lowy, Israel
Uldrick, Thomas
Miller, Elizabeth
O'Cearbhaill, Roisin
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (SUPPL_4) : A9 - A10
[2] Ubamatamab (REGN4018, MUC16xCD3 bispecific antibody) monotherapy in patients with recurrent ovarian cancer (OC): Phase I dose-escalation analysis
Van Nieuwenhuysen, E.
O'Malley, D.
O'Cearbhaill, R. E.
Moore, K. N.
Hamilton, E. P.
Yeku, O.
Bouberhan, S.
Hou, J. Y.
Yoo, S-Y.
Brouwer-Visser, J.
Cheung, H. K.
Peterman, M.
Goncalves, P.
Schmidt, T.
Zhu, M.
Lowy, I.
Rowlands, T.
Uldrick, T. S.
Miller, E. A.
Liu, J. F.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S784 - S784
[3] A phase 1/2 study of ubamatamab (REGN4018), a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab (anti-PD-1) in patients with recurrent ovarian cancer or MUC16+endometrial cancer
Van Nieuwenhuysen, Els
Bouberhan, Sara
Papadimitriou, Konstantinos
Arend, Rebecca Christian
Lee, Jung-Yun
O'Cearbhaill, Roisin Eilish
O'Malley, David M.
You, Benoit
Martin, Antonio Gonzalez
Michels, Judith
Mileshkin, Linda R.
Lee, Yeh Chen
Miller, Rowan
Yoo, Suk-Young
Peterman, Mary Jane
Schmidt, Tamara
Knorr, David
Lowy, Israel
Uldrick, Thomas S.
Miller, Elizabeth
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[4] First-in-human phase 1/2 study of ubamatamab, a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer
Moore, Kathleen N.
Bouberhan, Sara
Hamilton, Erika P.
Liu, Joyce F.
O'Cearbhaill, Roisin Eilish
O'Malley, David M.
Papadamitriou, Konstantinos
Schroder, David
Van Nieuwenhuysen, Els
Yoo, Suk-Young
Peterman, Mary Jane
Goncalves, Priscila Hermont
Schmidt, Tamara
Zhu, Min
Lowy, Israel
Uldrick, Thomas S.
Miller, Elizabeth
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[5] A phase I/II study of ubamatamab (REGN4018), a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab (anti-PD-1) in patients with recurrent ovarian cancer or MUC16+endometrial cancer: Trial in progress update
Liu, Joyce
O'Malley, David
Van Nieuwenhuysen, Els
O'Cearbhaill, Roisin
Bouberhan, Sara
Moore, Kathleen
Hou, June
Hamilton, Erika
Yoo, Suk-Young
Wang, Bin
Peterman, Mary
Schmidt, Tamara
Knorr, David
Lowy, Israel
Uldrick, Thomas
Miller, Elizabeth
GYNECOLOGIC ONCOLOGY, 2024, 190 : S284 - S284
[6] First-in-human phase 1/2 study of ubamatamab, a MUC16XCD3 bispecific antibody, administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer
Moore, Kathleen
Bouberhan, Sara
Hamilton, Erika
Liu, Joyce
O'Cearbhaill, Roisin
O'Malley, David
Papadimitriou, Konstantinos
Schroder, David
Van Nieuwenhuysen, Els
Yoo, Suk-Young
Wang, Bin
Peterman, Mary
Goncalves, Priscila
Schmidt, Tamara
Zhu, Min
Lowy, Israel
Uldrick, Thomas
Miller, Elizabeth
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (SUPPL_4) : A254 - A255
[7] TRANSLATIONALFINDINGSFROM THE ONGOINGFIRST--IN--HUMAN (FIH) STUDY OF UBAMATAMAB (REGN4018, MUC16XCD3 BISPECIFIC ANTIBODY [BSAB]) IN PATIENTS (PTS) WITH RECURRENT OVARIAN CANCER: REGIMEN SELECTION.
Zhu, M.
Crawford, A.
Retter, M.
Toroghi, M. Khaksar
Conrado, D.
Brouwer--Visser, J.
Krueger, P.
Meng, X.
Davis, J.
Peterman, M.
Uldrick, T.
Miller, E.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S46 - S46
[8] TRANSLATIONAL FINDINGS FROM THE ONGOING FIRST-IN-HUMAN (FIH) STUDY OF UBAMATAMAB (REGN4018, MUC16XCD3 BISPECIFIC ANTIBODY [BSAB]) IN PATIENTS (PTS) WITH RECURRENT OVARIAN CANCER (OC): REGIMEN SELECTION
Zhu, M.
Crawford, A.
Retter, M.
Toroghi, M. Khaksar
Conrado, D.
Brouwer-Visser, J.
Krueger, P.
Meng, X.
Davis, J.
Peterman, M.
Uldrick, T.
Miller, E.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S59 - S59
[9] EVALUATION OF PHARMACOKINETICS (PK), SERUM CYTOKINES, AND SAFETY FOLLOWING INTRAVENOUS (IV) OR SUBCUTANEOUS (SC) STEP-UP DOSING OF UBAMATAMAB, A MUC16XCD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RECURRENT OVARIAN CANCER (OC)
Madia, P.
Conrado, D.
Brouwer-Visser, J.
Qin, Q.
Davis, J.
Uldrick, T.
Peterman, M.
Miller, E.
Zhu, M.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S65 - S65
[10] Exposure-biomarker analyses for cytokine release syndrome or infusion-related reaction, pain, and cytokine concentrations in serum during treatment with ubamatamab, a MUC16xCD3 bispecific antibody, among patients with recurrent ovarian cancer
Madia, Priyanka
Brouwer-Visser, Jurriaan
Qin, Qiao
Conrado, Daniela
Davis, John
Uldrick, Thomas
Peterman, Mary
Miller, Elizabeth
Zhu, Min
GYNECOLOGIC ONCOLOGY, 2024, 190 : S287 - S287

← 1 2 3 4 5 →